Rituximab, plasma exchange and immunoglobulins: an ineffective treatment for chronic active antibody-mediated rejection

BACKGROUND: Chronic active antibody-mediated rejection (c-aABMR) is an important cause of allograft failure and graft loss in long-term kidney transplants. METHODS: To determine the efficacy and safety of combined therapy with rituximab, plasma exchange (PE) and intravenous immunoglobulins (IVIG), a...

Descripción completa

Detalles Bibliográficos
Autores principales: Piñeiro, Gastón J, De Sousa-Amorim, Erika, Solé, Manel, Ríos, José, Lozano, Miguel, Cofán, Frederic, Ventura-Aguiar, Pedro, Cucchiari, David, Revuelta, Ignacio, Cid, Joan, Palou, Eduard, Campistol, Josep M, Oppenheimer, Federico, Rovira, Jordi, Diekmann, Fritz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182805/
https://www.ncbi.nlm.nih.gov/pubmed/30309322
http://dx.doi.org/10.1186/s12882-018-1057-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182805/
https://www.ncbi.nlm.nih.gov/pubmed/30309322
http://dx.doi.org/10.1186/s12882-018-1057-4

Ejemplares similares